Erythroblastic transformation of chronic myelogenous leukemia associated with an additional chromosome abnormality translocation (6;9

N. Awaya, M. Takao, H. Natsuda, T. Yamawaki, N. Suzuki, N. Takayama, A. Ishida, Y. Kawai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 57-year-old female was diagnosed being in the blastic phase of chronic myelogenous leukemia (CML) on her second admission in May 1993. The patient was previously treated with vincristine and prednisolone in the accelerated phase of CML in December 1991 without improvement. Other chemotherapeutic agents such as BHAC-DMP (enocitabine, daunorubicin, mercaptopurine, prednisolone), interferon, mercaptopurine and ranimustine were also administered. After the second chronic phase was achieved, she was treated with busulfan as an outpatient. On her second admission, the diagnosis of erythroblastic transformation was made, and cytogenetic study revealed t(9;22) (q34;q11) with the additional chromosomal abnormalities, t(6;9) (p23;q34). This karyotype rearrangement has been reported neither in Ph-positive CML nor in blastic crisis.

Original languageEnglish
Pages (from-to)1300-1304
Number of pages5
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume36
Issue number11
Publication statusPublished - 1995 Nov

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Erythroblastic transformation of chronic myelogenous leukemia associated with an additional chromosome abnormality translocation (6;9'. Together they form a unique fingerprint.

  • Cite this

    Awaya, N., Takao, M., Natsuda, H., Yamawaki, T., Suzuki, N., Takayama, N., Ishida, A., & Kawai, Y. (1995). Erythroblastic transformation of chronic myelogenous leukemia associated with an additional chromosome abnormality translocation (6;9. [Rinshō ketsueki] The Japanese journal of clinical hematology, 36(11), 1300-1304.